dinsdag, juli 23, 2019

Diagnoptics Technologies B.V.

Diagnoptics develops and markets non-invasive diagnostic technologies to assess cardiovascular risk and the risk of diabetes. The extensively validated AGE Reader enables a doctor to non-invasively assess the cardiovascular risk of their patients within 12 seconds. The technology is extensively validated in >200 scientific publications and is currently being marketed internationally.


Website: diagnoptics.com

Postadres
p/a de heer J. Kamps
Hoendiepskade 25
9718 BH Groningen

[E] info@gjsmidfonds.nl
[W] www.gjsmidfonds.nl